Results: 4

1.
Figure 4

Figure 4. From: Methylation of the Candidate Biomarker TCF21 Is Very Frequent Across A Spectrum of Early Stage Non-Small Cell Lung Cancers.

TCF21 protein expression. (A) TCF21 immunohistochemical expression in lung cancer. NSCLC samples were stained with an anti-TCF21 antibody and scored as none, low, medium, or high. Representative examples of SCC and adenocarcinoma samples with high TCF21 expression (left) and no TCF21 staining (right) are shown. (B) Frequency of TCF21 expression in NSCLC on the TMA (300 patients). The percentage of samples in each expression category is shown. Reduced expression was defined as “none” or “low”.

Kristy L. Richards, et al. Cancer. ;117(3):606-617.
2.
Figure 3

Figure 3. From: Methylation of the Candidate Biomarker TCF21 Is Very Frequent Across A Spectrum of Early Stage Non-Small Cell Lung Cancers.

Reactivation of TCF21 expression by demethylating agent decitabine. Quantitative TaqMan mRNA real-time PCR results interrogating exon junctions of exons 1/2 and exons 2/3 in three colorectal cancer cell lines with high methylation levels (>85%) with and without decitabine treatment are shown.

Kristy L. Richards, et al. Cancer. ;117(3):606-617.
3.
Figure 2

Figure 2. From: Methylation of the Candidate Biomarker TCF21 Is Very Frequent Across A Spectrum of Early Stage Non-Small Cell Lung Cancers.

Methylation levels and percent of tumors with methylation levels >30% threshold. (A) TCF21 promoter methylation levels are shown in a box and whisker plot for 42 normal adjacent lung tissues, 42 NSCLC tumors, 63 additional NSCLC tumors, all 105 NSCLC tumors combined, and 24 HNSCC tumors. (B) Bar graph representing the number of NSCLC and HNSCC tumors exceeding the 30% threshold for hypermethylation.

Kristy L. Richards, et al. Cancer. ;117(3):606-617.
4.
Figure 1

Figure 1. From: Methylation of the Candidate Biomarker TCF21 Is Very Frequent Across A Spectrum of Early Stage Non-Small Cell Lung Cancers.

Methylation levels of individual cancer cell lines, normal PBMCs, and positive and negative methylation controls. TCF21 promoter methylation levels are shown for 22 cancer cell lines, four pools of PBMCs of different sex (male, female) and age (≤40, >40 yrs). Control samples, fully methylated by treatment with SssI methylase or fully unmethylated by whole genome amplification, are also shown.

Kristy L. Richards, et al. Cancer. ;117(3):606-617.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk